Corporate Overview

Pathway Therapeutics is a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases.

The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor and the first compound with this profile to enter the clinic. Dual inhibition of PI3K and mTOR shuts down the PI3K/mTOR pathway more effectively than single target inhibitors. Of the four PI3K isoforms, PI3K alpha is the key isoform involved in the growth of solid tumors. PI3K alpha is commonly mutated and amplified across a broad range of tumor types and it is also the key isoform involved in signaling downstream of receptor tyrosine kinases. PWT33597 is also a superior mTOR inhibitor as it inhibits both mTOR complexes 1 and 2 (mTORC1 and mTORC2) to turn off a feedback loop that upregulates PI3K when only mTORC1 (target of rapalogs) is inhibited. With its selective and potent inhibition of PI3K alpha and mTOR, PWT33597 is expected to effectively shut down the dysregulated pathway in tumors and have an improved safety profile without off target toxicities.

Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies, inflammatory and respiratory diseases.

Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K/mTOR pathway inhibition. The profile of PWT33597 supports clinical development in tumors with PI3K alpha pathway dysregulation, (such as breast, endometrial, colorectal cancer, etc.) and mTOR driven tumors (such as renal cell carcinoma, endometrial, sarcoma, neuroendocrine tumors, etc.). This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration.

Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing and FDA approval of an IND for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months.

Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $17 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA